Academic pharmacist Nataly Martini highlights the importance of understanding non-Hodgkin lymphoma and pharmacists’ roles in managing this condition
Friday 1 November 2024, 01:00 AM
14 minutes to Read
Kava: A relaxing beverage with therapeutic benefits
Wednesday 1 June 2022, 12:15 AM
The kava plant in Maui, Hawaii [Image: Forest and Kim Starr, CC BY-SA 3.0]
Pharmacist and medical herbalist Phil Rasmussen traces the chequered history of kava, which is famous for its anti-anxiety and sleep-promoting properties
Kava (Piper methysticum) was first domesticated in the Pacific Islands about 3000 years ago. Numerous varieties exist, and today it is widely cultivat
References
- Hansel R, Beiersdorff HV. Arzneim Forsch 1959;9:581.
- Keller F, Klohs MW. Lloydia 1963;26:1.
- Meyer HJ. Kin Wochenschr 1965;43:469–70.
- Kretzschmar R. In: Loew D, Rietbrock N (eds). Phytiopharmaka in Forschung und Klinischer Anwendung, p29–38. Darmstadt, Germany: Verlag Steinkopff; 1995.
- Garrett KM, Basmadjian G, Khan IA, et al. Extracts of kava (Piper methysticum) induce acute anxiolytic-like behavioral changes in mice. Psychopharmacology 2003;170(1):33–41.
- Krum BN, Molz de Freitas C, Chiapinotto Ceretta AP, et al. Kava decreases the stereotyped behavior induced by amphetamine in mice. J Ethnopharmacol 2021;265:113293.
- Scholing WE, Clausen HD. On the effect of d,l-kavain: experience with neronika. Med Klin 1977;72(32–33):1301–06.
- Kinzler E, Krömer J, Lehmann E. Effect of a special kava extract in patients with anxiety-, tension-, and excitation states of non-psychotic genesis. Double blind study with placebos over 4 weeks]. Arzneimittelforschung 1991;41(6):584–88.
- Lindenberg D, Pitule-Schodel H. D,L-kavain in comparison with oxazepam in anxiety disorders. A double-blind study of clinical effectiveness. Forschr Med 1990;108:49.
- Warnecke G., Psychosomatic dysfunctions in the female climacteric. Clinical effectiveness and tolerance of Kava extract WS 1490. Fortschr Med 1991;109:119–22.
- Volz HP, Keiser M. Kava-kava extract WS 1490 versus placebo in anxiety disorders – a randomised placebo-controlled 25 week outpatient trial. Pharmacopsychiatry 1997;30(1):1–5.
- Pittler MH, Ernst E. Efficacy of kava extract for treating anxiety: systematic review and meta-analysis. J Clin Psychopharmacol 2000;20(1):84–89.
- Witte S, Loew D, Gaus W. Meta-analysis of the efficacy of the acetonic kava-kava extract WS1490 in patients with non-psychotic anxiety disorders. Phytotherapy Res 2005;19(3):183–88.
- Smith K, Leiras C. The effectiveness and safety of Kava Kava for treating anxiety symptoms: A systematic review and analysis of randomized clinical trials. Complementary Therapies in Clinical Practice 2018;33:107–17.
- Sarris J, Byrne GJ, Bousman CA, et al. Kava for generalised anxiety disorder: A 16-week double-blind, randomised, placebo-controlled study. Aust N Z J Psychiatry 2020;54(3):288–97.
- Holm E. The action profile of D,L-kavain. Cerebral sites and sleep-wakefulness-rhythm in animals. Arzneimittelforschung 1991;41(7):673–83.
- Davies LP, et al. Kava pyrones and resin: studies on GABAA, GABAB and benzodiazepine binding sites in rodent brain. Pharmacol Toxicol 1992;71(2):120–26.
- Jussofie A, et al. Kavapyrone enriched extract from Piper methysticum as modulator of the GABA binding site in different regions of rat brain. Psychopharmacology 1994;116(4):469–74.
- Boonen G, Haberlein H. Influence of genuine kavapyrone enantiomers on the GABA-A binding site. Planta Medica 1998;64:504–06.
- Walden J, et al. Effects of kawain and dihydromethysticin on field potential changes in the hippocampus. Prog Neuropsychopharmacol Biol Psychiatry 1997;21(4):697–706.
- Baum SS, Hill R, Rommelspacher H. Effect of kava extract and individual kavapyrones on neurotransmitter levels in the nucleus accumbens of rats. Prog Neuropsychopharmacol Biol Psychiatry 1998;22(7):1105–20.
- Dinh LD, Simmen U, Bueter KB, et al. Interaction of various Piper methysticum cultivars with CNS receptors in vitro. Planta Med 2001;67(4):306–11.
- Wang Y, Su C, Zhang B, et al. Biological activity, hepatotoxicity, and structure-activity relationship of kavalactones and flavokavins, the two main bioactive components in kava (Piper methysticum). Evid Based Complement Alternat Med 2021;2021:6851798.
- Singh YN. Kava: an overview. J Ethnopharmacol 1992;37(1):13–45.
- Huck O, You J, Han X, et al. Reduction of articular and systemic inflammation by kava-241 in a Porphyromonas gingivalis-induced arthritis murine model. Infection and Immunity 2018;86(9):e00356–18.
- Botello JF, Corral P, Bian T, et al. Kava and its kavalactones inhibit norepinephrine-induced intracellular calcium influx in lung cancer cells. Planta Medica 2020;86(1):26–31.
- Bian T, Ding H, Wang Y, et al. Suppressing the activation of protein kinase A as a DNA damage-independent mechanistic lead for dihydromethysticin (DHM) prophylaxis of NNK-induced lung carcinogenesis. Carcinogenesis 2022:bgac031.
- Pan H, Liu F, Wang J, et al. Dihydromethysticin, a natural molecule from Kava, suppresses the growth of colorectal cancer via the NLRC3/PI3K pathway. Molecular Carcinogenesis 2020;59(6):575–89.
- Jandial DD, Krill LS, Chen L, et al. Induction of G2M arrest by flavokawain A, a kava chalcone, increases the responsiveness of HER2-overexpressing breast cancer cells to herceptin. Molecules (Basel, Switzerland) 2017;22(3):462.
- Stevinson C, Huntley A, Ernst E. A systematic review of the safety of kava extract in the treatment of anxiety. Drug Safety 2002;25(4):251–61.
- LaPorte E, Sarris J, Stough C, et al. Neurocognitive effects of kava (Piper methysticum): a systematic review. Human Psychopharmacology 2011;26(2):102–11.
- Sarris J, Laporte E, Scholey A, et al. Does a medicinal dose of kava impair driving? A randomized, placebo-controlled, double-blind study. Traffic Inj Prev 2013;14(1):13–17.
- Norton SA, Ruze P. Kava dermopathy. J Am Acad Dermatol 1994;31(1):89–97.
- Duffield PH, Jamieson D. Development of tolerance to kava in mice. Clin Exp Pharmacol Physiol 1991;18(8):571–78.
- Teschke R. Kava hepatotoxicity--a clinical review. Ann Hepatol 2010;9(3):251–65.
- Schmidt M, Morgan M, Bone K, et al. Kava: A risk-benefit assessment. In: Mills S, Bone K (eds). The Essential Guide to Herbal Safety, pp. 155–221. St. Louis, MO: Elsevier, Churchill, Livingstone; 2005.
- Schmidt M. German court ruling reverses kava ban; German regulatory authority appeals decision. HerbalGram 2014;103:38–42.
- Kuchta K, Schmidt M, Nahrstedt A. German kava ban lifted by court: The alleged hepatotoxicity of kava (Piper methysticum) as a case of ill-defined herbal drug identity, lacking quality control, and misguided regulatory politics. Planta Med 2015;81(18):1647–53.
- Thomsen M, Schmidt M. Health policy versus kava (Piper methysticum): Anxiolytic efficacy may be instrumental in restoring the reputation of a major South Pacific crop. J Ethnopharmacol 2021;268:113582.
- NZ Association of Medical Herbalists, Rasmussen PL. Submission to the MCC concerning proposal to harmonise the classification of kava with that of Australia. May 2005.
- Natural Health Products New Zealand, Rasmussen PL. Submission to FSANZ concerning proposed changes to the food standard regulating kava use. 22 December 2021.
Class
Hosted Content 2
Chemist Warehouse is sponsoring the Young Pharmacist of the Year Award in the 2025 New Zealand Primary Healthcare Awards | He Tohu Mauri Ora. The Chemist Warehouse leadership team explains what it means to be a Stellar Supporter
Thursday 20 February 2025, 08:03 AM
1 minute to Read
Latest issue
